deltatrials
Active Not Recruiting PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT01208389

Phase 1 Follow-on Study of AAV2-hRPE65v2 Vector in Subjects With Leber Congenital Amaurosis (LCA) 2

A Follow-On Study to Evaluate the Safety of Re-Administration of Adeno-Associated Viral Vector Containing the Gene for Human RPE65 [AAV2-hRPE65v2] to the Contralateral Eye in Subjects With Leber Congenital Amaurosis (LCA) Previously Enrolled in a Phase 1 Study

Sponsor: Spark Therapeutics, Inc.

Conditions Leber Congenital Amaurosis
Interventions voretigene neparvovec-rzyl
Updated 15 times since 2017 Last updated: Apr 24, 2025 Started: Nov 30, 2010 Primary completion: Oct 31, 2027 Completion: Oct 31, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Leber Congenital Amaurosis, this trial is ongoing. The trial is conducted by Spark Therapeutics, Inc. and has accumulated 15 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshot~Apr 2017 – ~Apr 2018 · 12 months · monthly snapshot~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~Aug 2019 · 14 months · monthly snapshot~Aug 2019 – ~Jan 2021 · 17 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Sep 2022 · 17 months · monthly snapshot~Sep 2022 – ~Oct 2023 · 13 months · monthly snapshot~Oct 2023 – ~Apr 2024 · 6 months · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jan 2025 · 4 months · monthly snapshot~Jan 2025 – ~May 2025 · 4 months · monthly snapshot~May 2025 – present · 14 months · monthly snapshot

Change History

15 versions recorded

  1. May 2025 — Present [monthly]

    Active Not Recruiting PHASE1/PHASE2

  2. Jan 2025 — May 2025 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  3. Sep 2024 — Jan 2025 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  5. Apr 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

▶ Show 10 earlier versions

  1. Oct 2023 — Apr 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  2. Sep 2022 — Oct 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  3. Apr 2021 — Sep 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  4. Jan 2021 — Apr 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Aug 2019 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  6. Jun 2018 — Aug 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  7. Apr 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  8. Apr 2017 — Apr 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  9. Feb 2017 — Apr 2017 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  10. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    First recorded

Nov 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Spark Therapeutics, Inc.
Data source: Spark Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations